Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase – Time to Buy?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw unusually-strong trading volume on Tuesday . Approximately 2,754,421 shares traded hands during trading, an increase of 90% from the previous session’s volume of 1,448,977 shares.The stock last traded at $21.6150 and had previously closed at $19.72.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Major sell‑side firms kept constructive ratings despite cuts to targets — Jefferies trimmed its price target from $114 to $63 but remains a “buy.” Jefferies lowers PT to $63
• Positive Sentiment: Wells Fargo lowered its target from $65 to $45 but kept an “overweight” rating, signaling some analysts still see upside vs. the re‑priced stock. Wells Fargo lowers PT to $45
• Neutral Sentiment: Company statement: Ultragenyx released top‑line Phase 3 ORBIT and COSMIC results confirming neither study achieved the primary endpoint (reduction in annualized clinical fracture rate vs. placebo or bisphosphonates). GlobeNewswire: Phase 3 ORBIT and COSMIC Results
• Neutral Sentiment: Trading reaction: RARE was temporarily halted for a news release prior to the session and then resumed under heavy volume, reflecting rapid investor repricing. Reuters: Drug fails late-stage trials
• Negative Sentiment: Core setback: Multiple outlets report setrusumab failed to reduce fracture rate — the central clinical objective for OI — undermining the drug’s commercial case and potential peak sales. PharmaLetter: Phase III disappoints
• Negative Sentiment: Financial/operational impact: Reports say the failed study erased more than $1B from market value and Ultragenyx announced “significant” cutbacks to reduce cash burn. BizJournals: vows cutbacks, market value hit
• Negative Sentiment: Market sentiment and investor actions: Coverage highlights large intraday declines, analyst target cuts and sell-side/long‑holder rebalancing (e.g., articles explaining why investors are selling). Seeking Alpha: why I’m selling

Analyst Ratings Changes

Several equities analysts recently commented on RARE shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Barclays lowered their price objective on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, November 24th. Jefferies Financial Group dropped their target price on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.57.

Ultragenyx Pharmaceutical Price Performance

The company has a 50-day moving average of $33.66 and a two-hundred day moving average of $32.11. The company has a market capitalization of $2.08 billion, a PE ratio of -3.64 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The company had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The firm’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period last year, the business earned ($1.40) EPS. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the company’s stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at $3,095,132.77. This represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Parallel Advisors LLC increased its position in Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 669 shares during the last quarter. Assetmark Inc. grew its stake in Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank raised its position in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares in the last quarter. Danske Bank A S bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at about $39,000. Finally, Smartleaf Asset Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.